Your session is about to expire
← Back to Search
Histone Deacetylase Inhibitor
Biomarker Guided Treatment in DLBCL
Phase 2
Waitlist Available
Research Sponsored by Ruijin Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Approved for 60 Other Conditions
Summary
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma
Eligible Conditions
- Non-Hodgkin's Lymphoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 60 Other Conditions
This treatment demonstrated efficacy for 60 other conditions.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: RCHOPXExperimental Treatment9 Interventions
Group II: RCHOPActive Control5 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vincristine
FDA approved
Decitabine
FDA approved
Cyclophosphamide
FDA approved
Prednisone
FDA approved
Tucidinostat
Not yet FDA approved
Ibrutinib
FDA approved
Rituximab
FDA approved
Doxorubicin
FDA approved
Lenalidomide
FDA approved
Find a Location
Who is running the clinical trial?
Ruijin HospitalLead Sponsor
633 Previous Clinical Trials
1,347,006 Total Patients Enrolled